Zoetis Adds AI Urine Sediment Analysis To Vetscan Imagyst® Platform

0

  • Vetscan Imagyst is the first and only AI-driven diagnostics technology to provide five applications in a single platform, offering analysis at the point of care

  • The new feature helps enable veterinarians to make timely and accurate treatment decisions for pets

Zoetis, Inc. recently announced the expansion of its multi-application diagnostics platform, Vetscan Imagyst®, to include AI Urine Sediment analysis. The new application will enable accurate, in-clinic sediment analysis of fresh urine, allowing clinicians to make treatment decisions quickly.1 Powered by deep learning artificial intelligence (AI), Vetscan Imagyst AI Urine Sediment analysis offers veterinarians consistent, accurate results within minutes,1 for optimal individualized treatment plans that benefit both pets and pet owners. The launch of this newest application broadens the wide range of high-value, in-clinic diagnostics made possible by Vetscan Imagyst, helping veterinarians provide the best possible care for their canine and feline patients.

Dr. Richard Goldstein

“Vetscan Imagyst is powered by cutting-edge AI, and AI Urine Sediment analysis offers the promise of expert-level results within minutes, streamlining workflows and allowing the veterinary team to spend more time with their patients,” said Richard Goldstein, DVM, DACVIM, DECVIM-CA, Vice President and Chief Medical Officer, Global Diagnostics Medical Affairs at Zoetis. “The addition of our newest application makes Vetscan Imagyst an even more powerful tool in the clinic. Its deep learning AI will help in the visualization and identification of urine sediment elements, which are often difficult to capture using traditional urine sediment examinations.”

About Vetscan Imagyst, An All-in-One Technology

Launched by Zoetis in 2020, Vetscan Imagyst is a first-of-its-kind technology, offering multiple applications in a single platform. Using a compact scanner along with AI technology and backed up by a global network of expert clinical pathologists, Vetscan Imagyst efficiently delivers a variety of consistent diagnostic tests, including AI Fecal, AI Blood Smear, AI Dermatology, Digital Cytology, and now AI Urine Sediment. Vetscan Imagyst also offers access to add-on remote expert clinical pathologists* and specialist consultations for in-depth case reviews when needed.

Vetscan Imagyst AI Urine Sediment

The American Animal Hospital Association (AAHA) guidelines recommend a urinalysis as part of routine diagnostic health screenings for pets.2,3 Even with this guidance in mind, a separate 2023 survey that evaluated both sick and well pets found that only 32% of veterinarians included urinalysis in every or almost every health screening. Further, veterinarians cited financial concerns, the belief that a urinalysis was not warranted, and difficulty obtaining urine as barriers to performing a urinalysis.4 The Vetscan Imagyst AI Urine Sediment application is designed to alleviate the challenges surrounding workflow, lack of trained staff, and the time it takes to read urine sediments.

The application includes a validated sample preparation method and algorithm evaluation to provide more consistent, thorough urine sediment results. This includes an evaluation of red blood cells and white blood cells, squamous and other epithelial cells (e.g., urothelial and renal tubular epithelial cells), hyaline and non-hyaline casts, struvite and calcium oxalate dihydrate crystals and cocci and rod bacteria comparable to that of a clinical pathologist.1 The system provides a succinct report, including pictures that can be shared with pet owners. Beyond aiding in diagnosis, the detailed reports produced by the AI Urine Sediment application help drive compliance with prescribed treatment.

“Urinalysis must be performed as quickly as possible after urine collection, in order to limit detection of artifacts and to improve the identification of delicate elements that otherwise will degrade, which makes point-of-care sediment analysis a fundamental service offering for pet practices,” said Dennis Chew, DVM, DACVIM, Emeritus Professor at The Ohio State University College of Veterinary Medicine. “The emergence of new AI-driven technologies like Vetscan Imagyst has enhanced the ability of the veterinary care team to perform these vital screenings in the clinic within minutes, making it easier for timely and accurate treatment decisions for pets, and providing peace of mind for pet owners to get results quickly.”

Veterinarians and their healthcare team can visit www.zoetisdiagnostics.com to learn more about Zoetis Diagnostics solutions and Vetscan Imagyst AI Urine Sediment to learn more about this innovative all-in-one technology.

*Additional charges may apply.

[i] Nationwide®. Skin allergies, ear infections among most common conditions that prompt veterinary visits. Available at: https://news.nationwide.com/common-pet-conditions-that-prompt-veterinary-visits. Accessed February 2023.
[ii] Data on File. Vetstreet/Covetrus Pruritus Projection Trend. March 2019. Zoetis Inc.
[iii] Zoetis U.S. Market Research. Study: Impact of Vetscan Imagyst AI Diagnostic Tool on Current Cytology Testing Landscape. July 2022.
[iv] Nationwide®. Skin allergies, ear infections among most common conditions that prompt veterinary visits. Available at: https://news.nationwide.com/common-pet-conditions-that-prompt-veterinary-visits. Accessed December 2022.
[v] Zoetis U.S. Market Research. Study: Impact of Vetscan Imagyst AI Diagnostic Tool on Current Cytology Testing Landscape. July 2022.
[vi] Data on File. Vetstreet/Covetrus Pruritus Projection Trend. March 2019. Zoetis Inc.
[vii] Kynetec PetTrak – GAH-284: Unique Canine Patients Since Launch Custom Report: Apoquel and Cytopoint – September, 2022.
[viii] Zoetis Data on File. Study Report No. D870R-US-22-053.
[ix] Zoetis. IMAGYST Digital Cytology Turnaround Times Based On Internal Zoetis Data Pull As Of 11/28/2022. November 2022.
[x] Zoetis Data on File. Study Report No. DHX6Z-US-22-131 (D6131).
Source: Zoetis Press Release
Share.

Leave A Reply